세계의 바이오마커 시장 : 제공별, 유형별, 연구 분야별, 기술별, 질환별, 용도별 예측(-2030년)

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

"The predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market in 2024."

The market by type is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. This large share is supported by the ability of predictive biomarker-based offerings to guide treatment decisions and improve clinical outcomes by identifying patients most likely to benefit from a particular therapeutic intervention, which is especially valuable in oncology, autoimmune disorders, and infectious diseases. Moreover, the growing number of companion diagnostic approvals linked to predictive biomarkers further reinforced their adoption across healthcare settings. For instance, Roche's PATHWAY anti-HER2/neu (4B5) test identifies HER2-low breast cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion in January 2025 to identify HER2-ultralow patients in HR-positive, HER2-negative metastatic breast cancer.

"Immunoassays held the largest share in the biomarker technologies market in 2024."

The biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, immunoassays held the largest market share in the biomarkers market due to their high specificity and ability to detect various biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Scalability and automation capabilities further support high-throughput testing, meeting the rising demand for precision diagnostics. Major companies are actively advancing immunoassay platforms to enhance their diagnostic offerings. For instance, Roche offers the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

"The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period."

The Asia Pacific is projected to register the highest growth rate in the biomarkers market during the forecast period. Key drivers of this growth include a large patient population undergoing advanced medical testing and supportive healthcare policies to improve cancer care. Additionally, increased research activity by pharmaceutical and biotechnology companies to develop novel drug therapies is expected to accelerate market expansion. As investment in drug development continues to rise across the region, the demand for biomarkers that support drug discovery and development efforts is growing steadily.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), and Laboratory Corporation of America Holdings (US) are some of the key players in the biomarkers market.

The study includes an in-depth competitive analysis of these key players in the biomarkers market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the biomarkers market by offering [consumables (assay kits, columns & filters, reagents & chemicals), services, and software], type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology [immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies], disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (increasing use of biomarkers in drug discovery & development, growing importance of companion diagnostics, rising prevalence of cancer, developments of biomarkers for rare diseases, increasing funds and grants for biomarker research, advancement in omics technologies), restraints (high capital investments and extensive timelines for biomarker development, disease complexity, and heterogeneity), opportunities (growing preference for personalized medicine and precision oncology, enhanced collaboration among healthcare providers and key industry players, high growth potential of emerging economies), and challenges (issues associated with quantification and validation of biomarkers, complexities associated with data set integration, technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), and Quanterix (US), among others, in the biomarkers market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 STUDY SCOPE
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOMARKERS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING
• 4.3 BIOMARKERS MARKET SHARE, BY END USER, 2024
• 4.4 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 MARKET DRIVERS
    • 5.2.1.1 Increasing use of biomarkers in drug discovery & development
    • 5.2.1.2 Growing importance of companion diagnostics
    • 5.2.1.3 Rising prevalence of cancer
    • 5.2.1.4 Development of biomarkers for rare diseases
    • 5.2.1.5 Increasing funds and grants for biomarker research
    • 5.2.1.6 Advancement in omics technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investments and extensive timelines for biomarker development
    • 5.2.2.2 Disease complexity and heterogeneity
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for personalized medicine and precision oncology
    • 5.2.3.2 Enhanced collaboration among healthcare providers and key industry players
    • 5.2.3.3 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with quantification & validation of biomarkers
    • 5.2.4.2 Complexities associated with data set integration
    • 5.2.4.3 Technical issues related to sample collection and storage
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY ANALYSIS
  • 5.4.1 REGULATORY SCENARIO
    • 5.4.1.1 US
    • 5.4.1.2 Europe
    • 5.4.1.3 Asia Pacific
    • 5.4.1.4 Rest of the World
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGICAL ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Immunoassays
      • 5.6.1.1.1 Immunohistochemistry (IHC)
      • 5.6.1.1.2 ELISA
    • 5.6.1.2 Next-generation Sequencing (NGS)
    • 5.6.1.3 Polymerase chain reaction (PCR)
    • 5.6.1.4 In situ hybridization
    • 5.6.1.5 Microarrays
    • 5.6.1.6 Mass Spectrometry
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Liquid biopsy
    • 5.6.2.2 CRISPR
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Artificial intelligence (AI) and machine learning (ML)
    • 5.6.3.2 Sensors (wearable devices)
• 5.7 PRICING ANALYSIS
  • 5.7.1 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024
  • 5.7.2 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024
• 5.8 PATENT ANALYSIS
  • 5.8.1 METHODOLOGY
  • 5.8.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025
• 5.9 ECOSYSTEM ANALYSIS
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 THREAT OF NEW ENTRANTS
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BIOMARKERS MARKET: BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 TRADE DATA ANALYSIS
  • 5.14.1 IMPORT SCENARIO: HS CODE 382200, 2020-2024
  • 5.14.2 EXPORT SCENARIO: HS CODE 382200, 2020-2024
• 5.15 IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 USE CASES
  • 5.15.3 FUTURE OF AI IN BIOMARKER ECOSYSTEM
• 5.16 IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET
  • 5.16.1 KEY TARIFF RATES
  • 5.16.2 PRICE IMPACT ANALYSIS
  • 5.16.3 IMPACT ON COUNTRIES/REGIONS
    • 5.16.3.1 US
    • 5.16.3.2 Europe
    • 5.16.3.3 Asia Pacific
  • 5.16.4 IMPACT ON END-USE INDUSTRIES
    • 5.16.4.1 Pharmaceutical & biotech companies
    • 5.16.4.2 Hospitals & diagnostic laboratories
    • 5.16.4.3 Contract research organizations

6 BIOMARKERS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 ASSAY KITS
    • 6.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
  • 6.2.2 REAGENTS & CHEMICALS
    • 6.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand
  • 6.2.3 OTHER CONSUMABLES
• 6.3 SERVICES
  • 6.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
• 6.4 SOFTWARE
  • 6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

7 BIOMARKERS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 SAFETY BIOMARKERS
  • 7.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH
• 7.3 EFFICACY BIOMARKERS
  • 7.3.1 PREDICTIVE BIOMARKERS
    • 7.3.1.1 Rising applications of biomarkers in personalized medicine to drive market
  • 7.3.2 SURROGATE BIOMARKERS
    • 7.3.2.1 Ability to serve as reliable indicator in place of clinical endpoints to support market growth
  • 7.3.3 PHARMACODYNAMIC BIOMARKERS
    • 7.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
  • 7.3.4 PROGNOSTIC BIOMARKERS
    • 7.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers
• 7.4 VALIDATION BIOMARKERS
  • 7.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

8 BIOMARKERS MARKET, BY RESEARCH AREA

• 8.1 INTRODUCTION
• 8.2 GENOMICS
  • 8.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
• 8.3 PROTEOMICS
  • 8.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
• 8.4 METABOLOMICS
  • 8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
• 8.5 OTHER RESEARCH AREAS

9 BIOMARKERS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 IMMUNOASSAYS
  • 9.2.1 ELISA
    • 9.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth
  • 9.2.2 PROTEIN MICROARRAYS
    • 9.2.2.1 Quick and cost-effective nature of technology to support growth
  • 9.2.3 WESTERN BLOT
    • 9.2.3.1 Increasing investments in proteomics research to drive market
• 9.3 NEXT-GENERATION SEQUENCING (NGS)
  • 9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
• 9.4 POLYMERASE CHAIN REACTION (PCR)
  • 9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
• 9.5 MASS SPECTROMETRY
  • 9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH
• 9.6 CHROMATOGRAPHY
  • 9.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
• 9.7 OTHER TECHNOLOGIES

10 BIOMARKERS MARKET, BY DISEASE INDICATION

• 10.1 INTRODUCTION
• 10.2 CANCER
  • 10.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
• 10.3 INFECTIOUS DISEASES
  • 10.3.1 INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND
• 10.4 IMMUNOLOGICAL DISORDERS
  • 10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET
• 10.5 NEUROLOGICAL DISORDERS
  • 10.5.1 WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH
• 10.6 CARDIOVASCULAR DISORDERS
  • 10.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
• 10.7 OTHER DISEASE INDICATIONS

11 BIOMARKERS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 CLINICAL DIAGNOSTICS
  • 11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
• 11.3 DRUG DISCOVERY & DEVELOPMENT
  • 11.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
• 11.4 PERSONALIZED MEDICINE
  • 11.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
• 11.5 CLINICAL RESEARCH
  • 11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
• 11.6 OTHER APPLICATIONS

12 BIOMARKERS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES
  • 12.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
• 12.3 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 12.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
• 12.4 ACADEMIC & RESEARCH INSTITUTES
  • 12.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
• 12.5 OTHER END USERS

13 BIOMARKERS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 Rising focus on biopharma research to support growth
  • 13.2.3 CANADA
    • 13.2.3.1 Increasing incidence of cancer to drive biomarkers market growth
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Growth in biopharmaceutical R&D activities to propel growth
  • 13.3.3 UK
    • 13.3.3.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
  • 13.3.4 FRANCE
    • 13.3.4.1 Increasing government investment for proteomics & genomics research to drive growth
  • 13.3.5 ITALY
    • 13.3.5.1 Increasing developments in life science research to fuel growth
  • 13.3.6 SPAIN
    • 13.3.6.1 R&D initiatives for personalized medicine to support market growth
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Rising incidence of CVD to propel market
  • 13.4.3 JAPAN
    • 13.4.3.1 Strong regulatory guidelines for drug discovery & development to support market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Favorable scenario for FDI and increasing number of clinical trials to propel market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Increasing innovations in NGS technologies to support market growth
  • 13.4.6 AUSTRALIA
    • 13.4.6.1 Increasing demand for diagnostic solutions to propel market
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Increased government investments in pharmaceutical R&D to drive market
  • 13.5.3 MEXICO
    • 13.5.3.1 Rising demand for chronic disease treatment to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 13.6.2 GCC COUNTRIES
  • 13.6.3 SAUDI ARABIA
    • 13.6.3.1 Growing healthcare expenditure to boost market growth
  • 13.6.4 UAE
    • 13.6.4.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth
  • 13.6.5 REST OF GCC COUNTRIES
    • 13.6.5.1 Other GCC countries include Bahrain, Kuwait, Oman, and Qatar.
  • 13.6.6 REST OF MIDDLE EAST
    • 13.6.6.1 The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq.
• 13.7 AFRICA
  • 13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
  • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
• 14.3 REVENUE ANALYSIS, 2022-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Offering footprint
    • 14.5.5.4 Technology footprint
    • 14.5.5.5 Application footprint
• 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of key startups/SMEs
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 VALUATION OF KEY PLAYERS
  • 14.7.2 FINANCIAL METRICS OF KEY PLAYERS
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.8.1 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 THERMO FISHER SCIENTIFIC INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products & services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches & approvals
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 MERCK KGAA
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products & services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
      • 15.1.2.3.2 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products & services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches & approvals
      • 15.1.3.3.2 Deals
  • 15.1.4 QIAGEN
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products & services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches & approvals
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
  • 15.1.5 ABBOTT
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products & services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches & approvals
      • 15.1.5.3.2 Deals
  • 15.1.6 AGILENT TECHNOLOGIES, INC.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products & services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product launches & approvals
      • 15.1.6.3.2 Deals
  • 15.1.7 REVVITY INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products & services offered
  • 15.1.8 CHARLES RIVER LABORATORIES
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products & services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 BIO-RAD LABORATORIES, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products & services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product launches
      • 15.1.9.3.2 Deals
  • 15.1.10 EUROFINS SCIENTIFIC
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products & services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Deals
  • 15.1.11 BIOMERIEUX
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products & services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches & approvals
      • 15.1.11.3.2 Deals
  • 15.1.12 ILLUMINA, INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products & services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches & approvals
      • 15.1.12.3.2 Deals
  • 15.1.13 JSR CORPORATION
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products & services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Deals
  • 15.1.14 GUARDANT HEALTH
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products & services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches & approvals
      • 15.1.14.3.2 Deals
  • 15.1.15 LABCORP
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products & services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Product launches
  • 15.1.16 QUANTERIX
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products & services offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Product launches
      • 15.1.16.3.2 Deals
  • 15.1.17 MESO SCALE DIAGNOSTICS, LLC
    • 15.1.17.1 Business overview
    • 15.1.17.2 Products & services offered
• 15.2 OTHER PLAYERS
  • 15.2.1 CELERION
  • 15.2.2 STANDARD BIOTOOLS
  • 15.2.3 SEBIA
  • 15.2.4 BIOAGILYTIX LABS
  • 15.2.5 STRESSMARQ BIOSCIENCES INC.
  • 15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC
  • 15.2.7 SIGNOSIS
  • 15.2.8 SERIMMUNE
  • 15.2.9 THERAINDX LIFESCIENCES PVT. LTD.
  • 15.2.10 SYNEXA LIFE SCIENCES BV
  • 15.2.11 DIATECH PHARMACOGENETICS
  • 15.2.12 SINGULEX, INC.
  • 15.2.13 R-BIOPHARM AG

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS